FDA Advisory Panel Backs BPC-157 and KPV. Why That Does Not Make Peptide Compounding Legal Today.

If you run a compounding pharmacy, a med spa, a telehealth platform, or a peptide retail business, today's vote is going to be sold to you as permission. It is not. The FDA's Pharmacy Compounding Advisory Committee recommended adding BPC-157 and KPV to the Section 503A Bulks List by a single vote, over the written objection of the agency's own scientists. Your legal position did not change today. What changed is the number of people who will assume it did, and that assumption is where federal exposure gets manufactured.

PCAC voted 8-6 with one abstention to recommend BPC-157 and KPV for the 503A Bulks List, over the written objection of FDA's own review staff. A recommendation is not an addition.

Key Takeaways

• PCAC voted 8-6 with one abstention on July 23, 2026 to recommend BPC-157 and KPV for the Section 503A Bulks List.
• The vote is advisory. Compounding these substances stays outside the 503A exemption under 21 U.S.C. 353a until final rulemaking.
• Preparations made from ineligible bulk substances are unapproved and misbranded drugs under 21 U.S.C. 355 and 21 U.S.C. 352.
• South Florida med spas, telehealth platforms, and pharmacies face the highest near-term risk from expanding volume during an unauthorized window.
• Florida prescribers carry parallel state exposure under the Patient Brokering Act, Fla. Stat. 817.505, for commission-based compensation.

What Actually Happened at White Oak

The Pharmacy Compounding Advisory Committee met at FDA's White Oak campus in Silver Spring to consider whether seven peptides belong on the Section 503A Bulk Drug Substances List. Day one covered BPC-157, KPV, TB-500, and MOTs-C.

The committee voted 8-6 in favor with one abstention on BPC-157, and returned an identical count on KPV. Each substance drew two separate votes because both a free base and an acetate form were under review.

FDA career review staff had recommended against all seven. Applying the four-factor framework at 21 C.F.R. 216.23, they concluded none met the criteria, citing inadequate characterization, inconsistent naming conventions, and thin or absent human clinical evidence. For KPV, TB-500, and MOTs-C, staff found no human data at all.

The committee went the other way. Public comment ran close to two hours, predominantly from clinicians whose businesses offer peptide therapy and from compounding pharmacy industry representatives.

FDA's own scientists recommended against all seven peptides under the four-factor framework at 21 C.F.R. 216.23. The committee voted the other way by one member. Prosecutors will read both records.

What the Vote Does, and What It Does Not Do

A PCAC recommendation is advisory. FDA decides. If the agency accepts it, the agency must then amend the 503A Bulks List through notice-and-comment rulemaking under the Administrative Procedure Act. That process runs twelve months at the fast end and routinely longer.

Until a final rule issues, BPC-157 and KPV occupy exactly the position they occupied yesterday. Section 503A, codified at 21 U.S.C. 353a, exempts compounded preparations from new drug approval, current good manufacturing practice, and labeling requirements only when the bulk drug substance satisfies one of three conditions: it complies with a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 503A Bulks List. These peptides satisfy none of the three today. A recommendation to add is not an addition.

Where the Criminal Exposure Sits

When a compounded preparation falls outside the 503A exemption, it becomes an unapproved new drug under 21 U.S.C. 355 and a misbranded drug under 21 U.S.C. 352. Introducing or delivering it into interstate commerce violates 21 U.S.C. 331. Penalties run under 21 U.S.C. 333, which sets a strict liability misdemeanor requiring no proof of intent, and a felony carrying up to three years where the government establishes intent to defraud or mislead.

That is the floor. The charges actually filed in these matters tend to be broader. Where patient-facing marketing overstates regulatory status or clinical evidence, the government reaches for wire fraud under 18 U.S.C. 1343. Where a federal health care program or a private insurer is billed, health care fraud under 18 U.S.C. 1347 carries ten years per count. Multi-party arrangements among a pharmacy, a telehealth platform, and a prescriber invite conspiracy charges under 18 U.S.C. 371.

Prescribers sit differently than compounders. A physician writing patient-specific prescriptions is not introducing an article into interstate commerce, so direct FDCA liability is thin. Exposure arrives through aiding and abetting and conspiracy, and it turns on knowledge.

Exposure also arrives faster at the state level. Florida DOH can pursue unprofessional conduct and prescribing outside prevailing standards under the Nurse Practice Act without waiting on a federal case, on a lower burden and a far shorter timeline.

Florida operators carry an additional layer. Commission-based compensation tied to patient origination creates criminal exposure under the Florida Patient Brokering Act, Fla. Stat. 817.505. The bona fide employee and personal services safe harbors do not reach independent contractor structures as they are commonly written. A flat-rate W-2 arrangement is the compliant form.

The Mistakes That Will Get Made This Week

Reading a headline as authorization. Some version of "FDA panel approves BPC-157" will run in a great many places over the next seventy-two hours. That is not what happened. A committee recommended. The agency has not acted.

Expanding volume now. This is the one that creates cases. An operator who scales marketing and dispensing in the weeks after a favorable advisory vote generates a documented spike in conduct during a period when no legal pathway existed. Prosecutors will not have to reconstruct that record. The operator builds it for them.

Treating the indication as irrelevant. The committee reviewed BPC-157 for ulcerative colitis. It did not bless recovery, longevity, athletic performance, or general wellness. Even under a favorable final rule, promotion for uses outside the reviewed indication remains a misbranding problem under 21 U.S.C. 352 and a substantiation problem at the Federal Trade Commission.

Assuming a patient-specific prescription solves it. It satisfies one condition of 503A and does nothing about substance eligibility. This is the most common misunderstanding among prescribers working in this area, and it is the one that produces the worst surprises.

What Defense Looks Like at This Stage

Nearly every peptide matter that becomes a federal prosecution passes through a long pre-indictment phase first. That phase is where these cases are won or lost.

The work is document-driven. Who represented what, to whom, and when. Where the active pharmaceutical ingredient came from. What the pharmacy told the prescriber about eligibility, and whether any of it is in writing. What the consent forms disclosed. Whether the compensation structure survives federal anti-kickback analysis and Fla. Stat. 817.505.

"A prescriber holding written confirmation from a pharmacy about sourcing and regulatory status stands in a materially different position than one who assumed. Good faith reliance is a real defense in this space, and it is documentary."— Aaron M. Cohen, Principal Attorney

Good faith reliance holds even where the pharmacy's representation turned out to be wrong. The government has to prove state of mind, and a paper trail showing reasonable inquiry cuts directly against it.

Why the Next Ninety Days Matter

Two clocks are running.

The regulatory clock. FDA will act, and the shape of that action defines what a compliant model looks like. Operators who position now, with documented consents, clean compensation structures, and written sourcing confirmations, can move quickly when a rule issues. Those who do not will be reconstructing records under subpoena.

The enforcement clock. FDA has been working this space through warning letters. Warning letters build notice, and notice is what converts a regulatory violation into a knowing one. An operator who received one and continued presents a very different case than one who did not.

The window where conduct is still fluid, where charging decisions have not been made, and where counsel can affect the outcome is open right now. It closes without announcement.

Common Questions

AMC Defense Law represents compounding pharmacies, telehealth platforms, med spa operators, physicians, and advanced practice nurses in federal investigations and prosecutions involving FDA enforcement, health care fraud, and compounded drug distribution. The firm handles matters in Florida and nationwide, including pre-indictment representation, target letter response, and grand jury practice.

The window where charging decisions are still fluid is open right now. It closes without announcement.

If you or your loved ones are under federal investigation involving peptides, GLP-1 compounds, or med spa operations in Florida, call Aaron M. Cohen, 24 hours a day to get help.

This article is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by reading this content. Regulatory status described here reflects developments as of July 23, 2026 and is subject to change.